aTyr Pharma to Participate in ROTH Capital Partners Webinar on COVID-19 Therapeutics in Development on October 28th
Details of the event are as follows:
Event: ROTH Capital Partners Webinar on COVID-19 Therapeutics in Development
Panel: Immune Modulators to Ameliorate COVID-19
Registration for the webinar is available on the Investor’s section of the Company’s website at www.atyrpharma.com. A replay of the live webcast will be available on the Company’s website following the event.
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.
Source: aTyr Pharma, Inc.